H.C. Wainwright analyst Raghuram Selvaraju lowered the firm’s price target on Rockwell Medical (RMTI) to $7 from $9 and keeps a Buy rating on the shares post the Q3 report. The company’s largest customer made a special premium products order, but expects future volumes to decline due to supplier diversification, the analyst tells investors in a research note.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on RMTI:
- Rockwell Medical expands distribution in the Philippines
- Rockwell Medical initiated with a Buy at Rodman & Renshaw
- Rockwell Medical Reports Strong Q3 2024 Earnings
- Rockwell Med Reveals Strategic Corporate Presentation
- Rockwell Medical raises 2024 revenue view to $98.0M-$101.0M from $95.0M-$98.0M
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
